<DOC>
	<DOCNO>NCT02566525</DOCNO>
	<brief_summary>Prospective , multi-center , randomize , feasibility clinical study . Subjects randomize 1:1 ratio either standard care ( SOC ) alone standard care treatment CytoSorbÂ® device .</brief_summary>
	<brief_title>CytoSorb Reduction Free Hemoglobin During Cardiac Surgery</brief_title>
	<detailed_description />
	<criteria>Elective , cardiac surgery require cardiopulmonary bypass anticipate duration &gt; 180 minute Platelet count &lt; 20,000/ uL Body mass index &lt; 18 Pregnant woman Life expectancy &lt; 14 day End stage organ disease Active infection Undergoing cardiac transplant ventricular assist device explant , isolated primary coronary artery bypass grafting ( CABG ) single valve procedure Contraindication anticoagulation heparin Declined informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>CytoSorb device</keyword>
	<keyword>Plasma free hemoglobin</keyword>
	<keyword>inflammation</keyword>
	<keyword>extracorporeal bypass</keyword>
</DOC>